Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CannaWell is a cannabinoid-based therapeutic candidate developed by Cannabis Bioscience International Holdings (CBIH) for the treatment of epilepsy. The formulation is designed to leverage the anticonvulsant properties of phytocannabinoids, primarily by modulating neuronal excitability through the endocannabinoid system and non-canonical receptors. Its mechanism of action likely involves the antagonism of G protein-coupled receptor 55 (GPR55) and the desensitization of transient receptor potential vanilloid 1 (TRPV1) channels, both of which are implicated in seizure activity. CBIH aims to provide standardized, pharmaceutical-grade cannabis extracts to ensure consistent dosing and efficacy in patients with refractory epilepsy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CannaWell.